Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company focuses on developing therapeutics for rare cardiovascular conditions. The company is developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida. Show more

Location: 822 A1A North, Ponte Vedra, FL, 32082, United States | Website: https://www.cadrenal.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

25.41M

52 Wk Range

$5.70 - $22.90

Previous Close

$13.00

Open

$12.94

Volume

26,636

Day Range

$12.27 - $13.40

Enterprise Value

16.36M

Cash

7.336M

Avg Qtr Burn

-2.542M

Insider Ownership

29.34%

Institutional Own.

7.52%

Qtr Updated

03/31/25

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Tecarfarin Details End-Stage Renal Disease , Systemic thromboembolism, Atrial fibrillation	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tecarfarin Details Left Ventricular Assist Devices Patients	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.